Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08EQD
|
|||
| Drug Name |
FGF401
|
|||
| Synonyms |
Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341
Click to Show/Hide
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1/2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1/2 | [1] | ||
| Company |
Novartis Oncology East Hanover, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H30N8O4
|
|||
| Canonical SMILES |
CN1CCN(C(=O)C1)CC2=C(N=C3C(=C2)CCCN3C(=O)NC4=NC=C(C(=C4)NCCOC)C#N)C=O
|
|||
| InChI |
1S/C25H30N8O4/c1-31-7-8-32(23(35)15-31)14-18-10-17-4-3-6-33(24(17)29-21(18)16-34)25(36)30-22-11-20(27-5-9-37-2)19(12-26)13-28-22/h10-11,13,16H,3-9,14-15H2,1-2H3,(H2,27,28,30,36)
|
|||
| InChIKey |
BHKDKKZMPODMIQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1708971-55-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | FGFR4 messenger RNA (FGFR4 mRNA) | Target Info | Antagonist | [1] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Panther Pathway | FGF signaling pathway | |||
| Pathway Interaction Database | FGF signaling pathway | |||
| Reactome | PI3K Cascade | |||
| PIP3 activates AKT signaling | ||||
| FGFR4 ligand binding and activation | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| Phospholipase C-mediated cascade | ||||
| FRS-mediated FGFR4 signaling | ||||
| SHC-mediated cascade:FGFR4 | ||||
| PI-3K cascade:FGFR4 | ||||
| Negative regulation of FGFR4 signaling | ||||
| RAF/MAP kinase cascade | ||||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | ||||
| PIP3 activates AKT signaling | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.